Neutralization of measles virus wild-type isolates after immunization with a synthetic peptide vaccine which is not recognized by neutralizing passive antibodies

被引:21
作者
El Kasmi, KC
Fillon, S
Theisen, DM
Hartter, H
Brons, NHC
Muller, CP
机构
[1] Lab Natl Sante, L-1011 Luxembourg, Luxembourg
[2] Univ Tubingen, Fak Med, D-72076 Tubingen, Germany
[3] Univ Tubingen, Fak Biol, D-72076 Tubingen, Germany
关键词
D O I
10.1099/0022-1317-81-3-729
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The sequence H379-410 of the measles virus haemagglutinin (MV-H) protein forms a surface-exposed loop and contains three cysteine residues (Cys-381, Cys-386 and Cys-394) which are conserved among all measles isolates. It comprises the minimal sequential B cell epitope (BCE) (H386-400) of the neutralizing and protective MAb BH6 that neutralizes all wild-type viruses tested. The aim of this study was to design synthetic peptides which induce neutralizing antibodies against MV wild-type isolates. Peptides containing one or two copies of T cell epitopes (TCE) and BCEs of different lengths (H386-400, B-cc; H379-400, B-ccc), in different combinations and orientations were produced and iteratively optimized for inducing neutralizing antibodies. Peptides with the shorter BCE induced sera that cross-reacted with MV but did not neutralize. The longer BCE containing the three cysteines (B-ccc) and two homologous TCE were required for neutralization activity. These sera neutralized wild-type strains of different clades and geographic origins. Neutralizing serum was also obtained after immunization with human promiscuous TCEs. Furthermore B-ccc-based peptides were fully immunogenic even in the presence of pre-existing MV-specific antibodies. The results suggest that subunit vaccines based on such peptides could potentially be used to actively protect infants against wild-type viruses irrespective of persisting maternal antibodies.
引用
收藏
页码:729 / 735
页数:7
相关论文
共 27 条
  • [1] PERSISTENCE OF MATERNAL ANTIBODY IN INFANTS BEYOND 12 MONTHS - MECHANISM OF MEASLES-VACCINE FAILURE
    ALBRECHT, P
    ENNIS, FA
    SALTZMAN, EJ
    KRUGMAN, S
    [J]. JOURNAL OF PEDIATRICS, 1977, 91 (05) : 715 - 718
  • [2] THE PREDICTED PRIMARY STRUCTURE OF THE MEASLES-VIRUS HEMAGGLUTININ
    ALKHATIB, G
    BRIEDIS, DJ
    [J]. VIROLOGY, 1986, 150 (02) : 479 - 490
  • [3] THE ANTIGENIC STRUCTURE OF PROTEINS - A REAPPRAISAL
    BENJAMIN, DC
    BERZOFSKY, JA
    EAST, IJ
    GURD, FRN
    HANNUM, C
    LEACH, SJ
    MARGOLIASH, E
    MICHAEL, JG
    MILLER, A
    PRAGER, EM
    REICHLIN, M
    SERCARZ, EE
    SMITHGILL, SJ
    TODD, PE
    WILSON, AC
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 1984, 2 : 67 - 101
  • [4] DEMOTZ S, 1989, J IMMUNOL, V142, P394
  • [5] A hemagglutinin-derived peptide-vaccine ignored by virus-neutralizing passive antibodies, protects against murine measles encephalitis
    El Kasmi, KC
    Theisen, D
    Brons, NHC
    Ammerlaan, W
    Klingele, M
    Truong, AT
    Muller, CP
    [J]. VACCINE, 1999, 17 (19) : 2436 - 2445
  • [6] El Kasmi KC, 1998, MOL IMMUNOL, V35, P905
  • [7] Antibodies to a new linear site at the topographical or functional interface between the haemagglutinin and fusion proteins protect against measles encephalitis
    Fournier, P
    Brons, NHC
    Berbers, GAM
    Wiesmuller, KH
    Fleckenstein, BT
    Schneider, F
    Jung, G
    Muller, CP
    [J]. JOURNAL OF GENERAL VIROLOGY, 1997, 78 : 1295 - 1302
  • [9] ROLE OF INDIVIDUAL CYSTEINE RESIDUES IN THE PROCESSING AND ANTIGENICITY OF THE MEASLES-VIRUS HEMAGGLUTININ PROTEIN
    HU, AH
    NORRBY, E
    [J]. JOURNAL OF GENERAL VIROLOGY, 1994, 75 : 2173 - 2181
  • [10] Characteristics of asymptomatic secondary immune responses to measles virus in late convalescent donors
    Huiss, S
    Damien, B
    Schneider, F
    Muller, CP
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1997, 109 (03) : 416 - 420